XML 71 R53.htm IDEA: XBRL DOCUMENT v3.20.4
Revenue - Revenue from Licensing Arrangements (Details) - USD ($)
1 Months Ended 3 Months Ended 12 Months Ended
Jun. 30, 2019
Dec. 31, 2020
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Collaborative Arrangements and Co-Promote Agreement                        
Milestone payment   $ 18,730,000 $ 18,257,000 $ 15,008,000 $ 19,862,000 $ 29,499,000 $ 12,427,000 $ 26,150,000 $ 5,338,000 $ 71,857,000 $ 73,414,000 $ 60,370,000
YUPELRI Monotherapy                        
Collaborative Arrangements and Co-Promote Agreement                        
Milestone payment   13,550,000 $ 12,960,000 $ 10,589,000 12,880,000 $ 10,352,000 $ 5,763,000 3,184,000 $ 1,000      
Viatris                        
Collaborative Arrangements and Co-Promote Agreement                        
Potential milestone or contingent payments         $ 1,500,000              
Upfront payment receivable $ 18,500,000                      
Number of performance obligations                   2    
Viatris | Sales milestones                        
Collaborative Arrangements and Co-Promote Agreement                        
Potential milestone or contingent payments 37,500,000 205,000,000.0           37,500,000   $ 205,000,000.0    
Viatris | Revefenacin Monotherapy (TD-4208)                        
Collaborative Arrangements and Co-Promote Agreement                        
Potential milestone or contingent payments   160,000,000.0               160,000,000.0    
Viatris | YUPELRI Monotherapy                        
Collaborative Arrangements and Co-Promote Agreement                        
Potential milestone or contingent payments 9,000,000.0             9,000,000.0        
Viatris | YUPELRI Monotherapy | Sales milestones                        
Collaborative Arrangements and Co-Promote Agreement                        
Potential milestone or contingent payments   150,000,000.0               150,000,000.0    
Viatris | Future potential combination products                        
Collaborative Arrangements and Co-Promote Agreement                        
Potential milestone or contingent payments 7,500,000 $ 45,000,000.0           7,500,000   $ 45,000,000.0    
Viatris | Future potential combination products | Development and Sales Milestones                        
Collaborative Arrangements and Co-Promote Agreement                        
Potential milestone or contingent payments $ 54,000,000.0             $ 54,000,000.0        
Pfizer                        
Collaborative Arrangements and Co-Promote Agreement                        
Number of performance obligations                   2    
Pfizer | Sales milestones                        
Collaborative Arrangements and Co-Promote Agreement                        
Milestone payment                     $ 240,000,000.0